The Filing Desk

Coya Therapeutics

COYA · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

COYA · Last close · November 19, 2026
$2.98
Value Coya Therapeutics yourself

Coya Therapeutics' revenue rose 123.6% to $8 million in fiscal 2025. Its operating margin was −283.9%, up from −485.4% a year earlier. The diluted share count rose 9.8%.

Coya Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001193125-26-107281 Updated
Revenue
$8M
123.6%
Operating margin
−283.9%
201.5 pts
Net income
−$21M
 
Free cash flow
—
 
Return on equity
−51.4%
11.8 pts
Market cap
$70M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Coya Therapeutics does

Coya Therapeutics is a clinical-stage biotechnology company: it develops drugs but has none approved for sale. Its work centers on regulatory T cells, or Tregs, a kind of white blood cell that calms the immune system's inflammatory responses. Coya says Tregs stop working properly in many brain, autoimmune and metabolic diseases, and it is trying to restore their function.

Its lead drug candidate, COYA 302, combines a low dose of interleukin-2, an immune-signaling protein, with a second immune drug, CTLA4-Ig. In December 2025 Coya began a Phase 2 trial of COYA 302 in amyotrophic lateral sclerosis (ALS), and in January 2026 the FDA accepted its application to test the drug in frontotemporal dementia. It also has early work on Treg cell therapy and on exosomes, tiny particles released by cells.

Coya has no product sales. It has funded itself mainly by selling shares, and its partner Dr. Reddy's paid it $7.5 million up front for rights to sell COYA 302 for ALS in many countries, with more payments possible. Coya lost $21.2 million in 2025. It has eight full-time employees and relies on contract research organizations and consultants for much of its work.

Its biggest risks, as it describes them

  • It has never sold a product, keeps losing money and needs to raise more capital, without which it may delay or stop its programs.
  • Its business depends on COYA 302 and its other Treg-based drug candidates, which may fail in trials or never win approval.
  • Targeting Tregs is a new approach to treating brain and autoimmune diseases, with significant scientific and manufacturing challenges.
  • Its reliance on Dr. Reddy's and on contract research groups and manufacturers to develop, make and sell its drugs.
  • Clinical trials may be delayed or fail, including through slow patient enrollment or serious side effects.
From Coya Therapeutics's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Coya Therapeutics lost money in fiscal 2025: a net loss of $21 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments46333847
Debt incl. finance leases—13———
Net debt (negative means net cash)—7———
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.0x1.9x8.2x11.6x8.5x
Quick ratio4.0x1.9x8.2x11.6x8.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Coya Therapeutics' filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Coya Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Coya Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''9.079.095.24
Accruals ratio12.9%−10.7%−22.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Coya Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Coya TherapeuticsFY25123.6%−283.9%————
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Xenon PharmaceuticalsFY25—−4,974.3%−3,732.2%———Compare
Ovid TherapeuticsFY251,181.3%−585.2%−528.6%———Compare
Palatin TechnologiesFY26—−98.2%−153.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue—0648
Revenue growth———−40.8%123.6%
Gross profit—————
Research and development2461217
Operating income−5−10−8−17−23
Net income−5−12−8−15−21
Diluted EPS (US$)−1.89−4.73−0.79−0.98−1.27
Diluted shares (millions)33101517
Cash flow
Cash from operations−4−7−11−10−11
Capital expenditure—————
Free cash flow—————
Dividends paid00000
Share buybacks00000
Acquisitions00000
Stock-based compensation00134
Balance sheet at fiscal year end
Cash and short-term investments46333847
Debt incl. finance leases—13———
Total assets58414450
Total liabilities117657
Shareholders' equity4−8364043
Margins and ratios
Gross margin—————
Operating margin——−131.7%−485.4%−283.9%
Net margin——−133.1%−418.7%−267.1%
Free cash flow margin—————
Rule of 40 (growth + FCF margin)—————
Return on capital—————
Return on equity——−58.6%−39.6%−51.4%
Return on assets—−185.7%−32.2%−34.8%−45.0%
Net debt to EBITDA—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Coya Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Coya Therapeutics.